U.S. Markets closed

These 4 Biotech Stocks Are Raising Eyebrows

CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The biotech industry is based on a framework made up of cunning edge medical technologies designed with the patient's best interests at heart. However, as with any industry, companies in biotech know that they can do better to create more treatment options and aim to contrive new approaches to how we offer biotechnological solutions for medical care. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Proteostasis Therapeutics, Inc (PTI), Alta Mesa Resources, Inc (AMR), and Stemline Therapeutics, Inc (STML) are 4 biotech stocks worth taking a look at.

Premier Health Group (OTC:PHGRF) (CSE:PHGI), as a company, recognizes the importance of meeting the demands and needs of its 100,000, and growing, active patient network. As an investment designed to provide the best quality of care for their network, the Company announced that, earlier this week, they had entered into a binding letter of intent agreement to acquire all the outstanding securities of Cloud Practice Inc.

In addition to this news, one of Premier's subsidiaries, HealthVue, is moving towards developing proprietary technology to deliver top-of-the-line healthcare through their network of interconnected primary clinics by way of integrating AI and telehealth technologies.

Dr. Essam Hamza , CEO of Premier Health, said ''We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.''

For More Information On Premier Health Group, Click Here

Proteostasis Therapeutics, Inc (PTI) a clinical stage biopharmaceutical company working tirelessly to create groundbreaking therapies to treat cystic fibrosis and other related ailments caused by dysfunctional protein processing, announced their most recent clinical enrollment update on Friday.

Per the Company's official press release regarding the enrollment update: "We believe a comprehensive data set from our proprietary doublet and triplet studies will provide evidence of the individual contribution of each drug candidate to the overall activity of the combinations, supporting Phase 3 dose selection rationale," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis. "In addition to our proprietary combinations, we remain as excited about our add-on portfolio, with both strategies reinforcing our commitment to expanding treatment options for CF patients. Given that the anticipated timing of these study readouts across this portfolio of programs remains Q1 2019, assuming positive results, we expect to be in a position to initiate Phase 3 studies within the next 12-18 months."

For More Information On Proteostasis Therapeutics, Inc, Click Here

Alta Mesa Resources, Inc (AMR) enjoyed impressive market gains on Friday as the Company's shares rose 17.51% to $0.98 per share in midday trading. The uptick may be a result of the Company's corporate restructuring of their C-level team, and subsequent announcement that James Hackett, the current Executive Chairman of the Board, will serve as interim Chief Executive Officer in the meantime.

Hackett spoke on the future of the company and its leadership team in an official press release which stated:

''We welcome Randy, John and Mark to Alta Mesa Resources, and I look forward to working with them in this transitional period for the company. This senior executive team has deep experience in public energy company leadership and understands the expectations demanded of those companies. All three are trained as petroleum engineers and have significant financial experience.''

For More Information on Alta Mesa Resources, Inc, Click Here

Stemline Therapeutics, Inc (STML), a biopharmaceutical company dead-set on developing new treatments via oncological therapeutics, presented updated information for its shareholders regarding its newest drug, ELZONRIS™ in early December. Based on the encouraging results from the update, the Company announced that a pivotal cohort is being developed for research purposes.

Ivan Bergstein, the Company's Chief Executive Officer, commented on the recent success of the ELZONRIS™ trials:

''The ELZONRIS clinical presentations showcased at ASH demonstrate a broad clinical potential in a wide range of malignancies. In particular, we believe that our data in relapsed/refractory CMML and MF provides important clinical proof-of-concept in two indications with unmet medical need, and underscores just two of the many potential expansion opportunities that targeting CD123 offers. At ASH, we continued to ramp-up our disease awareness campaign for BPDCN ahead of the upcoming FDA decision on the ELZONRIS BLA.

For More Information On Stemline Therapeutics, Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 ''4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

CONTACT

news@stockprice.com

SOURCE: Stock Price